Mirum Pharmaceuticals Inc (MIRM)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $6.14B
Last updated: Nov 17, 2026 at 11:05 AM ET
Mirum Pharmaceuticals Inc (MIRM) Earnings: Report Dates and Results
In the quarter ended Sep 30, 2026, Mirum Pharmaceuticals reported EPS of -$0.87, below the -$0.53 estimate. It beat the EPS estimate in 2 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
MIRM's report for the quarter ending Dec 31, 2026 is not on the earnings calendar yet.
MIRM Earnings Call
The latest MIRM earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 30 quarters below that had an estimate, MIRM beat 12 and missed 18. Revenue for the quarter ended Sep 30, 2026 was $185.72M, up 39.6% from $133.01M a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | -$0.87 | -$0.53 | -$0.53 - -$0.30 | -64.15% | Miss | -1840.0% | 2 | 0 up, 0 down | Nov 3, 2026 | $185.72M |
| Jun 30, 2026 | -$0.80 | -$0.77 | -$0.94 - -$0.50 | -3.90% | Miss | N/A | 5 | 0 up, 1 down | Aug 5, 2026 | $176.24M |
| Mar 31, 2026 | -$1.08 | -$0.35 | -$0.60 - -$0.14 | -208.57% | Miss | N/A | 6 | 0 up, 1 down | May 6, 2026 | $159.88M |
| Dec 31, 2025 | -$0.12 | -$0.05 | -$0.26 - $0.21 | -146.91% | Miss | N/A | 8 | 2 up, 0 down | Feb 25, 2026 | $148.93M |
| Sep 30, 2025 | $0.05 | -$0.16 | -$0.33 - $0.02 | +131.25% | Beat | N/A | 7 | 1 up, 0 down | Nov 4, 2025 | $133.01M |
| Jun 30, 2025 | -$0.12 | -$0.33 | -$0.50 - -$0.21 | +63.64% | Beat | N/A | 7 | 2 up, 4 down | Aug 6, 2025 | $127.78M |
| Mar 31, 2025 | -$0.30 | -$0.27 | -$0.44 - -$0.08 | -11.11% | Miss | N/A | 7 | 0 up, 1 down | May 7, 2025 | $111.58M |
| Dec 31, 2024 | -$0.49 | -$0.25 | -$0.41 - -$0.12 | -98.70% | Miss | N/A | 7 | 3 up, 0 down | Feb 26, 2025 | $99.41M |
| Sep 30, 2024 | -$0.30 | -$0.45 | -$0.61 - -$0.30 | +33.33% | Beat | N/A | 10 | 0 up, 0 down | Nov 12, 2024 | $90.38M |
| Jun 30, 2024 | -$0.52 | -$0.46 | -$0.57 - -$0.34 | -13.04% | Miss | N/A | 10 | 0 up, 0 down | Aug 7, 2024 | $77.88M |
| Mar 31, 2024 | -$0.54 | -$0.30 | -$0.73 - -$0.23 | -80.00% | Miss | N/A | 8 | 0 up, 0 down | May 8, 2024 | $69.22M |
| Dec 31, 2023 | -$0.66 | -$0.24 | -$0.50 - -$0.04 | -175.00% | Miss | N/A | 9 | 0 up, 0 down | Feb 28, 2024 | $69.55M |
| Sep 30, 2023 | -$0.57 | -$0.81 | -$0.81 - -$0.41 | +29.63% | Beat | N/A | 6 | 1 up, 1 down | Nov 2, 2023 | $47.73M |
| Jun 30, 2023 | -$0.65 | -$0.79 | -$0.89 - -$0.70 | +17.72% | Beat | N/A | 5 | 3 up, 0 down | Aug 3, 2023 | $37.50M |
| Mar 31, 2023 | -$0.80 | -$0.97 | -$1.08 - -$0.79 | +17.53% | Beat | N/A | 6 | 0 up, 0 down | May 4, 2023 | $31.60M |
| Dec 31, 2022 | -$0.99 | -$1.02 | -$1.52 - -$0.74 | +2.94% | Beat | N/A | 7 | 1 up, 0 down | Mar 8, 2023 | $27.91M |
| Sep 30, 2022 | -$1.02 | -$1.08 | -$1.21 - -$0.94 | +5.56% | Beat | N/A | 7 | 2 up, 0 down | Nov 9, 2022 | $18.78M |
| Jun 30, 2022 | -$0.84 | -$1.06 | -$1.69 - -$0.99 | +20.75% | Beat | N/A | 6 | 1 up, 1 down | Aug 4, 2022 | $17.48M |
| Mar 31, 2022 | -$1.17 | -$1.38 | -$1.53 - -$1.17 | +15.22% | Beat | N/A | 6 | 0 up, 1 down | May 5, 2022 | $12.89M |
| Dec 31, 2021 | -$1.66 | $0.35 | -$2.45 - $2.18 | -574.29% | Miss | N/A | 6 | N/A | Mar 9, 2022 | $3.14M |
| Sep 30, 2021 | -$1.60 | -$1.50 | -$2.46 - -$0.91 | -6.67% | Miss | N/A | 6 | N/A | Nov 15, 2021 | $5.00M |
| Jun 30, 2021 | -$1.45 | -$1.08 | -$1.60 - $1.13 | -34.26% | Miss | N/A | 6 | N/A | Aug 5, 2021 | $11.00M |
| Mar 31, 2021 | -$1.68 | -$0.98 | -$1.28 - $0.74 | -71.43% | Miss | N/A | 6 | N/A | May 6, 2021 | N/A |
| Dec 31, 2020 | -$1.43 | -$0.72 | -$1.13 - $0.76 | -98.61% | Miss | N/A | 7 | N/A | Mar 9, 2021 | N/A |
| Sep 30, 2020 | -$0.86 | -$0.98 | -$1.11 - -$0.94 | +12.24% | Beat | N/A | 6 | N/A | Nov 12, 2020 | N/A |
| Jun 30, 2020 | -$0.93 | -$0.87 | -$0.89 - -$0.83 | -6.90% | Miss | N/A | 4 | N/A | Aug 6, 2020 | N/A |
| Mar 31, 2020 | -$0.86 | -$0.84 | -$0.86 - -$0.76 | -2.38% | Miss | N/A | 4 | N/A | May 7, 2020 | N/A |
| Dec 31, 2019 | -$0.79 | -$0.85 | -$0.96 - -$0.75 | +7.06% | Beat | N/A | 4 | N/A | Mar 12, 2020 | N/A |
| Sep 30, 2019 | -$0.84 | -$0.63 | -$0.77 - -$0.50 | -33.33% | Miss | N/A | 4 | N/A | Nov 6, 2019 | N/A |
| Jun 30, 2019 | -$5.31 | -$0.57 | -$0.90 - -$0.39 | -831.58% | Miss | N/A | 4 | N/A | Jul 25, 2019 | N/A |
| Mar 31, 2019 | -$0.60 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | May 29, 2019 | N/A |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$0.49, after -$1.85 the year before. It was -$7.54 for the year ended Dec 31, 2019, the oldest of the 7 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$0.49 | N/A |
| Dec 31, 2024 | -$1.85 | N/A |
| Dec 31, 2023 | -$2.68 | N/A |
| Dec 31, 2022 | -$4.02 | N/A |
| Dec 31, 2021 | -$6.39 | N/A |
| Dec 31, 2020 | -$4.08 | N/A |
| Dec 31, 2019 | -$7.54 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 5,500 words across 20 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 5,450 | 20 | |
| 2026Q2 | Jun 30, 2026 | 5,248 | 17 | |
| 2026Q1 | Mar 31, 2026 | 5,097 | 18 | |
| 2025Q4 | Dec 31, 2025 | 3,677 | 14 | |
| 2025Q3 | Sep 30, 2025 | 4,094 | 15 | |
| 2025Q2 | Jun 30, 2025 | 4,411 | 16 | |
| 2025Q1 | Mar 31, 2025 | 3,851 | 13 | |
| 2024Q4 | Dec 31, 2024 | 3,985 | 12 |
2026Q3 Earnings Call
Opening remarks
Andrew McKibben SVP of Strategic Finance and Investor Relations Thank you, Joel, and good afternoon, everyone. I'd like to welcome you to Mirum Pharmaceuticals' Third Quarter 2026 Conference Call. I'm joined today by our Chief Executive Officer, Chris Peetz; our President and Chief Operating Officer, Peter Radovich; our Chief Medical Officer, Rob Myers; and our Chief Financial Officer, Eric Bjerkholt. Earlier today, Mirum issued a press release announcing the company's results for the third quarter of 2026. Copies of the press release and our SEC filings are available in the Investors section of our website. Before we start, I'd like to remind you that during the course of this conference call, we'll be making certain forward-looking statements based on management's current expectations, including statements regarding Mirum's programs and market opportunities for its approved medicines and product candidates, and financial guidance. These statements represent our judgment and knowledge of events as of today and inherently involve risks and uncertainties that may cause actual results to differ materially from the results discussed. We are under no duty to update these statements. Please refer to the risk factors in our latest Form 10-Q and subsequent SEC filings for more information about these risks and uncertainties. With that, I'd like to turn the call over to Chris. Chris?
Christopher Peetz CEO Thanks, Andrew. The third quarter was another strong period for Mirum, both commercially and across our clinical programs. We generated $186 million in third-quarter net product sales, and we are increasing our full-year net product sales guidance to $715 million to $720 million. We've also had great progress across the portfolio since our last earnings call: positive Phase III AZURE-1 data for Brelovitug, positive EXPAND data for LIVMARLI, the approval and launch of Atebrioz, and another positive Atebrioz readout in younger patients. Our recent progress feels quite meaningful as Mirum approaches its eighth anniversary. It's remarkable to think about what this team has accomplished in eight years. We started Mirum around a simple idea: by identifying important opportunities in rare diseases and combining great medicines with relentless execution, we could have a meaningful impact for patients and build an enduring company. Eight years later, we now have four approved medicines, a commercial business approaching $0.75 billion in annual net product sales, and a late-stage pipeline with multiple opportunities to drive our next phase of growth. Coming up, we have two more potentially registrational readouts approaching, with the Brelovitug AZURE-4 study in HDV expected this quarter and the volixibat VANTAGE study in PBC expected in the first quarter of next year. Together, these are part of five potential approvals and label expansions ahead of us as we work toward realizing the greater than $4 billion peak revenue potential of the Mirum portfolio.
Frequently Asked Questions About MIRM
Did MIRM beat earnings estimates last quarter?
No. Mirum Pharmaceuticals reported EPS of -$0.87 for the quarter ended Sep 30, 2026, below the -$0.53 estimate by 64.15%.
What EPS do analysts expect from MIRM next quarter?
The consensus EPS estimate for Mirum Pharmaceuticals for the quarter ending Dec 31, 2026 is -$0.59 from 15 analysts, with estimates from -$1.15 to -$0.12.
How often does MIRM beat earnings estimates?
Mirum Pharmaceuticals beat the EPS estimate in 2 of the last 8 quarters, with an average surprise of -42.31%.
MIRM pages: Overview, Earnings, Forecast, Financials, Competitors, Government Contracts